A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD); EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD); EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD); EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant; Stem Cell Transplant Complications; EBV+ Sarcomas; Leiomyosarcoma; Chronic Active Epstein-Barr Virus (CAEBV); Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH); Lymphohistiocytosis, Hemophagocytic
Intervention: Biological: Tabelecleucel
Sponsor: Atara Biotherapeutics
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
September 19, 2020 /
/ in Oncology